TABLE OF CONTENTS
1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 OVERVIEW OF NORTH AMERICA TOPICAL DRUG DELIVERY MARKET 25
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.6 MULTIVARIATE MODELLING 38
2.7 MARKET END USER COVERAGE GRID 39
2.8 PRODUCT LIFELINE CURVE 40
2.9 DBMR MARKET POSITION GRID 41
2.10 VENDOR SHARE ANALYSIS 42
2.11 SECONDARY SOURCES 43
2.12 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 PESTEL 48
4.2 PORTER'S FIVE FORCES MODEL 49
5 INDUSTRIAL INSIGHTS 50
6 PIPELINE ANALYSIS 51
7 EPIDEMIOLOGY 53
8 REGULATORY FRAMEWORK 54
9 MARKET OVERVIEW 55
9.1 DRIVERS 57
9.1.1 HIGH PREVALENCE OF SKIN DISEASES 57
9.1.2 RISING COMPANY ACTIVITIES IN DEVELOPING PRODUCTS AND INCREASING PRODUCT LAUNCHES 57
9.1.3 HIGH INCIDENCE OF BURN INJURIES 58
9.2 RESTRAINTS 58
9.2.1 CONTINUOUS IRRITATION ON THE SKIN AND ALLERGIES CAUSED BY TOPICAL DRUGS 58
9.2.2 DISCONTINUED PRODUCT RECALLS IN THE U.S. 59
9.3 OPPORTUNITIES 59
9.3.1 EXTENSIVE R&D ACTIVITIES IN DERMATOLOGY DRUGS 59
9.3.2 INCREASING INVESTMENT IN BIOLOGICS AND BIOSIMILARS 60
9.4 CHALLENGES 60
9.4.1 STRINGENT REGULATION FOR PRODUCT APPROVAL 60
9.4.2 ALTERNATIVE TO TOPICAL DRUGS FOR TREATMENT 61
10 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 62
10.1 OVERVIEW 63
10.2 DRUG DELIVERY FORMULATIONS 65
10.2.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS 66
10.2.1.1 OINTMENTS 67
10.2.1.2 CREAM 67
10.2.1.3 GELS 67
10.2.1.4 LOTIONS 67
10.2.1.5 PASTES 67
10.2.1.6 FOAM 67
10.2.1.7 OTHERS 67
10.2.2 LIQUID TOPICAL DRUG DELIVERY 67
10.2.2.1 SOLUTIONS 68
10.2.2.2 SUSPENSION 68
10.2.2.3 OTHERS 68
10.2.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS 68
10.2.3.1 POWDER 69
10.2.3.2 SUPPOSITORIES 69
10.2.3.3 OTHERS 69
10.3 DRUG DELIVERY SYSTEMS 69
10.3.1 TRANSDERMAL PATCHES 70
10.3.1.1 PASSIVE NON-INVASIVE PATCHES 71
10.3.1.1.1 RECTANGULAR 71
10.3.1.1.2 SQUARE 71
10.3.1.1.3 OTHERS 72
10.3.2 RESERVOIR 72
10.3.2.1 NITROGLYCERINE 72
10.3.2.2 OESTRADIOL 72
10.3.2.3 CLONIDINE 72
10.3.2.4 SCOPOLAMINE 72
10.3.2.5 OTHERS 72
10.3.3 MATRIX 72
10.3.3.1 NICOSTOP PATCH 73
10.3.3.2 ANGIDERM PATCH 73
10.3.3.3 OTHERS 73
10.3.4 DRUG IN-ADHESIVE 73
10.3.4.1 MULTI 73
10.3.4.2 SINGLE 74
10.3.5 NEXT GENERATION PATCHES 74
10.3.5.1 DISPOSABLE NFC BIOMARKER PATCHES 74
10.3.5.2 ZP-PTH RAPID DELIVERY PATCH 74
10.3.5.3 OTHERS 74
10.3.6 ACTIVE PATCHES 74
10.3.6.1 MICRONEEDLE PATCH 75
10.3.6.2 FENTANYL TRANSDERMAL PATCH 75
10.3.6.3 GLYCERALTRINITRATE (GTN) TRANSDERMAL PATCH 75
10.3.6.4 OTHERS 75
10.3.7 MINIMALLY INVASIVE PATCHES 75
10.3.7.1 GELATIN METHACRYLOYL MICRONEEDLE PATCH 76
10.3.7.2 UV PATCH 76
10.3.7.3 OTHERS 76
10.3.8 VAPOR PATCHES 76
10.3.8.1 VICKS VAPOR PATCH 77
10.3.8.2 NAZO VAPOR PATCH 77
10.3.8.3 RUNBUGZ VAPOR PATCH 77
10.3.8.4 OTHERS 77
10.3.9 NANOEMULSION GEL 77
10.3.9.1 MICROSPONGES 77
10.3.9.2 OTHERS 77
11 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DELIVERY TECHNIQUES 78
11.1 OVERVIEW 79
11.2 IONOTOPHORESIS 81
11.3 SONOPHORESIS 82
11.4 LASER ABLATION 82
11.5 RADIO FREQUENCY ABLATION 82
11.6 MAGNETOPHORESIS 83
11.7 ELECTROPORATION 83
11.8 OTHERS 84
12 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY MODE OF PURCHASE 85
12.1 OVERVIEW 86
12.2 OVER THE COUNTER 89
12.3 PRESCRIPTION 89
13 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY INDICATION 90
13.1 OVERVIEW 91
13.2 DERMATOLOGICAL DISORDERS 93
13.2.1 ACNE 94
13.2.2 ECZEMA 94
13.2.3 RINGWORM 95
13.2.4 ICHTHYOSIS 95
13.2.5 WARTS 95
13.2.6 PSORIASIS 95
13.2.7 ATOPIC DERMATITIS 95
13.2.8 PERIORAL DERMATITIS 95
13.2.9 PRESSURE SORES 95
13.2.10 ROSACEA 95
13.2.11 ATHLETES FOOT 95
13.2.12 OTHERS 95
13.3 OPHTHALMIC DISORDERS 96
13.3.1 CONJUNCTIVITIS 97
13.3.2 KERATITIS 97
13.3.3 EYE REDNESS 97
13.3.4 GLAUCOMA 97
13.3.5 BLEPHARITIS 97
13.3.6 IRITIS 97
13.3.7 MACULAR EDEMA 97
13.3.8 PUPILLARY DILATION 97
13.3.9 RETINOPATHY 97
13.3.10 STRABISMUS 97
13.3.11 OTHER 98
13.4 PAIN MANAGEMENT 98
13.5 HORMONAL THERAPY 98
13.6 NEUROLOGICAL DISORDERS 98
13.7 SMOKING CESSATION 99
13.8 OTHERS 99
14 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 100
14.1 OVERVIEW 101
14.2 DERMAL 103
14.3 OPHTHALMIC 104
14.4 RECTAL 104
14.5 VAGINAL 104
14.6 NASAL 105
14.7 OTHERS 105
15 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY TYPE 106
15.1 OVERVIEW 107
15.2 CLEANSING AGENTS 109
15.3 PROTECTIVE AGENTS 110
15.4 MOISTURIZING AGENTS (EMOLLIENTS) 110
15.5 DRYING AGENTS 110
15.6 ANTI-ITCH AGENTS 111
15.6.1 MENTHOL 112
15.6.2 PRAMOXINE 112
15.6.3 DOXEPIN 112
15.6.4 OTHERS 112
15.7 ANTI- INFLAMMATORY AGENTS 112
15.7.1 CORTICOSTEROIDS 113
15.7.2 CHAMOMILE 113
15.7.3 CALENDULA 113
15.7.4 OTHERS 113
15.8 ANTI-INFECTIVE AGENTS 113
15.8.1 TOPICAL ANTIBIOTICS 114
15.8.1.1 CLINDAMYCIN 114
15.8.1.2 ERYTHROMYCIN 115
15.8.1.3 METRONIDAZOLE 115
15.8.1.4 MUPIROCIN 115
15.8.1.5 BACITRACIN 115
15.8.1.6 POLYMYXIN 115
15.8.1.7 OTHERS 115
15.8.2 TOPICAL ANTIFUNGALS 115
15.8.2.1 KETOCONAZOLE 116
15.8.2.2 MICONAZOLE 116
15.8.2.3 ECONAZOLE 116
15.8.2.4 NYSTATIN 116
15.8.2.5 CICLOPIROX 116
15.8.2.6 TOLNAFTATE 116
15.8.2.7 TERBINAFINE 117
15.8.2.8 CLOTRIMAZOLE 117
15.8.2.9 OTHERS 117
15.8.3 NON-ANTIBIOTIC TOPICAL ANTISEPTICS 117
15.8.3.1 IODINE SOLUTIONS 117
15.8.3.2 GENTIAN VIOLET 117
15.8.3.3 ZINC PYRITHIONE 118
15.8.3.4 SILVER PREPARATIONS 118
15.8.3.5 OTHERS 118
15.9 KERATOLYTICS 118
15.9.1 SALICYLIC ACID 119
15.9.2 UREA 119
15.9.3 OTHERS 119
15.10 OTHERS 119
16 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY GENERATION 120
16.1 OVERVIEW 121
16.2 SECOND-GENERATION TRANSDERMAL DELIVERY SYSTEMS 123
16.3 FIRST-GENERATION TRANSDERMAL DELIVERY SYSTEMS 124
16.4 THIRD-GENERATION TRANSDERMAL DELIVERY SYSTEMS 125
17 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY END USER 126
17.1 OVERVIEW 127
17.2 HOME HEALTHCARE 129
17.3 SPECIALTY CENTRES 130
17.4 HOSPITAL 130
17.5 OTHERS 131
18 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 132
18.1 OVERVIEW 133
18.2 HOSPITAL PHARMACY 135
18.3 RETAIL PHARMACY 136
18.4 ONLINE PHARMACY 136
18.5 OTHERS 137
19 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET, BY COUNTRY 138
19.1 U.S. 156
19.2 CANADA 169
19.3 MEXICO 182
20 NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY LANDSCAPE 195
20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 195
21 SWOT ANALYSIS 196
22 COMPANY PROFILE 197
22.1 CRESCITA THERAPEUTICS INC 197
22.1.1 COMPANY SNAPSHOT 197
22.1.2 REVENUE ANALYSIS 197
22.1.3 PRODUCT PORTFOLIO 198
22.1.4 RECENT DEVELOPMENT 198
22.2 GSK PLC. 199
22.2.1 COMPANY SNAPSHOT 199
22.2.2 REVENUE ANALYSIS 199
22.2.3 PRODUCT PORTFOLIO 200
22.2.4 RECENT DEVELOPMENT 200
22.3 AGILE THERAPEUTICS 201
22.3.1 COMPANY SNAPSHOT 201
22.3.2 REVENUE ANALYSIS 201
22.3.3 PRODUCT PORTFOLIO 202
22.3.4 RECENT DEVELOPMENT 202
22.4 PFIZER INC. 203
22.4.1 COMPANY SNAPSHOT 203
22.4.2 REVENUE ANALYSIS 203
22.4.3 PRODUCT PORTFOLIO 204
22.4.4 RECENT DEVELOPMENT 204
22.5 ABBVIE INC. 205
22.5.1 COMPANY SNAPSHOT 205
22.5.2 REVENUE ANALYSIS 205
22.5.3 PRODUCT PORTFOLIO 206
22.5.4 RECENT DEVELOPMENT 206

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.